US Patent 8,987,441: Claim Scope, Patent Strength, Expiration, and Influenza Drug Landscape
US Patent 8,987,441 is a Shionogi patent directed to polycyclic compounds that inhibit influenza virus cap-dependent endonuclease. Its claims cover a broad chemical genus, selected salts and solvates, pharmaceutical compositions, anti-influenza activity, and cap-dependent endonuclease inhibition. The patent is relevant to the intellectual-property position for baloxavir-related products, including Xofluza, although exact product coverage must be confirmed against the missing structural figures and the patent’s disclosure.
What does US Patent 8,987,441 protect?
The patent protects compounds having a defined polycyclic core represented by formula (I), together with multiple permissible substituent classes. Claim 1 is the principal composition-of-matter claim.
The claim architecture has four controlling elements:
- A required formula (I) core.
- A broad set of permissible PR groups, including carbonyl, ester, carbamate, phosphate, phosphonate, ether, and related prodrug-forming groups.
- Broad substitution at R1a, R2a, R3a, R5a, R6a, and R7a.
- A ring-system limitation in which B1 is NR7a and B2 is CR5aR6a.
The claim also covers pharmaceutically acceptable salts and solvates. This extends the literal claim scope beyond the neutral parent compound to clinically useful solid and solution forms, subject to the requirement that the underlying molecular structure remains within formula (I).
What is the central inventive concept?
The central concept is a class of substituted polycyclic compounds that inhibit influenza polymerase cap-dependent endonuclease. Cap-dependent endonuclease is part of the influenza polymerase complex and is required for viral mRNA transcription.
The claims are not limited to one named compound. They cover a Markush genus containing:
- Heterocyclic and carbocyclic substituents.
- Tricyclic heterocyclic groups.
- Nitrogen-containing ring systems.
- Ester, carbonate, carbamate, amide, phosphate, and phosphonate derivatives.
- Solvates and pharmaceutically acceptable salts.
- Compounds with anti-influenza and cap-dependent endonuclease inhibitory activity.
The formula drawing is essential to a complete structure-level analysis. The text provided identifies the substituent definitions but does not reproduce the core structure or the structures referenced in claims 11, 12, 20, and 29. Those missing figures determine which commercial molecules fall within the literal scope.
How broad is claim 1 of US 8,987,441?
Claim 1 is materially broad at the genus level but constrained by the unidentified formula (I) core.
PR substituent coverage
The PR definitions cover a large range of parent and prodrug-like groups. The listed alternatives include:
| PR category |
Representative structural theme |
| a |
Acyl group with lower alkyl substitution |
| b |
Acyl group with carbocyclic, heterocyclic, aminoalkyl, or thioalkyl substitution |
| c-f |
Linker-containing acyl, ester, ether, and carbonate structures |
| g-i |
Carbonate, amide, and ether derivatives |
| j-u |
Extended ether, carbonate, carbamate, and phosphoric-acid derivatives |
| v |
Dibenzyl phosphate-type derivative |
| w |
Carbon-linked substituent other than benzyl |
| x-y |
Guanidinium or amidinium-type substituent |
This is important commercially because claims that expressly include ester, carbonate, carbamate, phosphate, and related groups can reach both an active parent compound and selected prodrug forms.
R1a coverage
R1a is broadly defined. The alternatives include:
- Hydrogen, halogen, hydroxy, carboxy, cyano, and formyl.
- Alkyl, alkenyl, alkynyl, alkoxy, carbonyl, and alkoxycarbonyl groups.
- Carbocyclic and heterocyclic groups.
- Amines, sulfonamides, ureas, carbamates, amides, sulfoxides, sulfones, and boronate-type groups.
Claims 2 through 5 progressively narrow R1a. Claim 5 is particularly narrow because it limits R1a to hydrogen or carboxy.
R2a coverage
R2a covers hydrogen, substituted hydrocarbons, carbocyclic and heterocyclic groups, and nitrogen- or sulfonyl-containing substituents. Claims 6 and 7 narrow this field, with claim 7 limiting R2a to hydrogen or substituted lower alkyl.
R3a coverage
R3a includes hydrogen, hydrocarbon groups, carbocyclic and heterocyclic groups, and multiple amide, sulfonamide, carbamate, and amino substituents.
Claims 8, 14, 15, 16, and 17 narrow R3a, with claim 15 limiting it principally to hydrogen or substituted lower alkyl. This creates a series of fallback positions if the broader genus is challenged.
B1, B2, and ring constraints
The required relationship is:
The patent permits R3a and R6a to form a heterocycle with an adjacent atom. Claims 23 and 24 specifically cover formation of a five- to seven-membered heterocycle.
This ring-closure feature is one of the most commercially important narrowing limitations. A competing molecule outside the permitted ring topology may avoid literal infringement even if it retains the same broad pharmacophore.
What do claims 2 through 29 add?
The dependent claims create layered protection around narrower chemical subgenuses.
| Claims |
Principal narrowing feature |
| 2-5 |
Narrower R1a definitions |
| 6-7 |
Narrower R2a definitions |
| 8 |
Narrower R3a definitions |
| 9-10 |
Defined R5a, R6a, and R7a substitution patterns |
| 11-12 |
Specific illustrated R7a structures and preferred combinations |
| 13-17 |
Consolidated preferred subgenera with narrower R1a-R3a and ring restrictions |
| 18-21 |
Tricyclic heterocyclic R7a groups and limited substituents |
| 22-24 |
R6a hydrogen or ring-forming limitations |
| 25-27 |
Narrower PR groups, including acyl, ester, carbonate, and alkyl/cyclic groups |
| 28-29 |
Highly defined combinations of PR, R1a-R3a, B1/B2, and R7a |
Claims 28 and 29 appear to be the most commercially focused chemical claims in the supplied claim set. They combine:
- R1a as hydrogen or carboxy.
- R2a as hydrogen or substituted lower alkyl.
- R3a as hydrogen or substituted lower alkyl.
- B1 as NR7a.
- B2 as CHR6a.
- R7a as a carbocyclic or heterocyclic group.
- A restricted set of PR groups.
- A defined R7a structure in claim 29.
These claims may provide stronger enforcement positions than claim 1 because they are less exposed to written-description and enablement attacks.
What pharmaceutical compositions are protected?
Claims 30 through 32 cover compositions containing compounds of the chemical claims.
Claim 30: composition claim
Claim 30 covers a pharmaceutical composition containing a compound within specified claims, including a pharmaceutically acceptable salt or solvate.
This claim is narrower than claim 1 because it depends on selected claims rather than incorporating every possible embodiment of claim 1. It can nevertheless be commercially significant because an approved oral drug product is ordinarily sold as a pharmaceutical composition containing the active ingredient and excipients.
Claim 31: anti-influenza activity
Claim 31 adds the limitation that the composition exhibits anti-influenza activity. This functional language may support infringement where the accused composition contains a claimed compound and demonstrates the specified activity. It does not appear to claim a treatment method because the claim is drafted as a composition claim.
Claim 32: cap-dependent endonuclease inhibition
Claim 32 requires cap-dependent endonuclease inhibitory activity. This links the composition to the pharmacological mechanism associated with influenza polymerase PA-subunit inhibition.
The claim does not appear to cover every cap-dependent endonuclease inhibitor. The compound must first satisfy the structural limitations incorporated through claim 30.
When does US Patent 8,987,441 expire?
The patent was granted on March 24, 2015. Public patent records associate the patent family with a March 31, 2011 priority date. On that basis, the nominal US patent term runs to approximately March 31, 2031, subject to any patent-term adjustment, terminal disclaimer, or other recorded term event. The Orange Book or USPTO Patent Center record should control the legally operative expiration date. [1][2]
| Event |
Date |
| Earliest reported priority date |
March 31, 2011 |
| US grant |
March 24, 2015 |
| Nominal 20-year term endpoint |
Approximately March 31, 2031 |
| Expected generic relevance |
Before 2031 only through challenge, settlement, invalidity, or non-infringement |
The patent is therefore materially relevant to generic-launch timing if it is listed against an approved product and if the marketed product falls within one or more unexpired claims.
What is the Orange Book status of US 8,987,441?
US 8,987,441 has been publicly associated with the Xofluza and baloxavir patent estate. The practical significance of an Orange Book listing depends on:
- The specific approved product.
- The patent-use code, if any.
- Whether the listing covers the active ingredient, formulation, method of use, or another approved-product attribute.
- Whether the patent remains unexpired.
- Whether a generic applicant files a Paragraph IV certification.
A composition-of-matter patent generally presents a stronger regulatory barrier than a narrow method-of-use patent because a generic product containing the same claimed compound may infringe regardless of whether the generic label includes the patented use.
The supplied claims are primarily compound and composition claims. They do not appear to be limited to a particular dosing schedule, patient population, or influenza strain.
Has there been a Paragraph IV challenge to this patent?
A complete current Paragraph IV assessment requires the live FDA Orange Book and litigation records. The supplied information does not establish a confirmed Paragraph IV certification, ANDA applicant, or filed infringement action directed specifically to US 8,987,441.
The relevant risk framework is:
- A generic applicant files an ANDA for an approved baloxavir product.
- The applicant certifies that the listed patent is invalid, unenforceable, or will not be infringed.
- The patent holder has 45 days to file an infringement action.
- A timely action can trigger a 30-month stay of final FDA approval under the Hatch-Waxman framework. [3]
A Paragraph IV certification against a composition-of-matter patent would generally present a higher litigation risk than a challenge limited to a formulation or method-of-use patent.
Which companies are challenging the patent?
No specific challenger can be identified from the claim text alone. Public FDA, PACER, and district-court records would be required to attribute a Paragraph IV certification or litigation to a particular company.
The commercial challengers most likely to matter are generic manufacturers pursuing baloxavir or Xofluza-equivalent products. A company could attempt to avoid infringement by:
- Selecting a compound outside the formula (I) core.
- Removing a claimed substituent relationship.
- Using a different ring system.
- Arguing that the commercial salt or solvate is outside the claims.
- Challenging written description, enablement, anticipation, obviousness, or indefiniteness.
- Pursuing a non-infringing alternative influenza endonuclease inhibitor.
How strong is the patent estate?
Strengths
The patent has several enforcement advantages:
- Claim 1 covers a large chemical genus.
- Salts and solvates are expressly included.
- Multiple prodrug and derivative groups are listed.
- Dependent claims create narrower fallback positions.
- Claims 28 and 29 target more defined commercial subgenera.
- Composition claims reach pharmaceutical products containing covered compounds.
- Claim 32 ties the composition to the relevant biological mechanism.
Weaknesses
The estate also has identifiable vulnerabilities:
- The independent claim is extremely complex.
- The supplied claim text contains apparent transcription and formatting errors.
- Several referenced structural figures are absent.
- The breadth of the Markush definitions may create written-description and enablement issues.
- Functional limitations in claims 31 and 32 may create proof issues.
- The patent’s value depends heavily on whether the approved commercial molecule falls within the narrower claims, not merely the broad genus.
- A later patent may provide stronger protection for the specific active ingredient, polymorph, formulation, or manufacturing process.
Overall, the patent appears strongest against a product that reproduces the patented core and preferred substituent pattern. Its position is weaker against a structurally differentiated inhibitor or against a generic product supported by a credible non-infringement position.
What patent landscape surrounds baloxavir and Xofluza?
The relevant patent landscape usually contains several layers:
| Layer |
Typical protection |
Strategic effect |
| Core compound |
Active ingredient or close analog |
Primary market-entry barrier |
| Prodrug |
Ester, carbonate, or related derivative |
Protects oral or pharmacokinetic form |
| Salt and solvate |
Solid-state or pharmaceutical form |
May restrict substitution |
| Formulation |
Tablets, granules, dosage compositions |
Product-specific barrier |
| Method of use |
Treatment of influenza or specified populations |
Label-dependent barrier |
| Manufacturing |
Chiral synthesis, intermediates, purification |
Can raise development and scale-up costs |
| Backup compounds |
Other endonuclease inhibitors |
Protects pipeline and licensing value |
US 8,987,441 is principally a core chemical and composition patent. It should therefore be analyzed together with later patents covering the exact approved active ingredient, its prodrug, solid form, formulation, manufacturing process, and approved use.
How does this patent compare with a formulation or method-of-use patent?
| Issue |
US 8,987,441 |
Formulation patent |
Method-of-use patent |
| Main subject |
Chemical compounds and compositions |
Dosage form or excipient system |
Treatment method |
| Product infringement risk |
High if molecule is claimed |
Depends on formulation replication |
Depends on label and use |
| Design-around potential |
Structural modification |
Alternative excipients or process |
Skinny label or different use |
| Regulatory relevance |
Potentially product blocking |
Product-specific |
Use-code and labeling dependent |
| Proof burden |
Structural identity and claim mapping |
Product composition and process |
Label, indication, and use evidence |
| Commercial durability |
Often stronger |
Usually narrower |
Often more vulnerable to label changes |
The broad chemical claims are generally more important than a narrow method claim when the product contains the exact claimed molecule.
What generic launch scenarios exist?
Scenario 1: launch after patent expiry
A generic applicant waits until the relevant patent and regulatory exclusivity periods expire. This is the lowest litigation-risk route but delays entry until approximately the early 2030s if the patent remains enforceable through its nominal term.
Scenario 2: Paragraph IV challenge
The applicant challenges validity or infringement before expiration. Potential arguments include:
- The marketed compound is outside the claim.
- The claims are anticipated by prior art.
- The genus is not enabled across its full scope.
- The specification does not adequately describe the claimed breadth.
- The claims are indefinite because of unclear structural terminology.
- A later-added limitation lacks support in the priority disclosure.
Scenario 3: settlement and licensed entry
The patent owner may agree to an authorized or negotiated entry date. The commercial value of such a settlement depends on the remaining patent term, regulatory exclusivity, market size, and the strength of the asserted claims.
Scenario 4: alternative active ingredient
A competitor develops a different cap-dependent endonuclease inhibitor that does not use the claimed formula (I) core. This avoids direct infringement but requires independent clinical, regulatory, and manufacturing investment.
What revenue exposure does the patent create?
The revenue exposure is tied to the commercial value of baloxavir products and the extent to which US 8,987,441 is a blocking patent rather than one member of a broader estate.
The key commercial variables are:
- US Xofluza sales.
- Seasonal influenza demand.
- Government stockpiling and public-health procurement.
- Pediatric and adult label expansion.
- Competition from oseltamivir and other antivirals.
- The number and scope of later-expiring patents.
- Whether a generic entrant can launch before the nominal 2031 expiry.
A composition-of-matter patent can support substantial revenue protection if it reads on the marketed active ingredient. If the patent covers only a broad research genus and later patents cover the commercial product more specifically, its standalone revenue contribution may be limited.
What geographic coverage does US 8,987,441 provide?
The patent provides protection only in the United States. Equivalent protection must be assessed separately in Japan, Europe, China, Canada, and other markets.
International analysis should compare:
- Priority and national-phase continuity.
- Grant status.
- Claim scope by jurisdiction.
- Patent-term adjustment or supplementary protection certificates.
- Opposition or invalidity proceedings.
- Local Orange Book or equivalent linkage mechanisms.
- Local generic filing and launch rules.
A US patent does not prevent manufacture, sale, or export in a foreign country unless corresponding national rights exist.
What manufacturing and IP barriers remain?
Even if a generic defeats or avoids US 8,987,441, commercial launch may remain constrained by:
- Chiral synthesis of the polycyclic core.
- Control of regioisomer and stereoisomer impurities.
- Preparation of the required ester or prodrug.
- Stable salt or solvate selection.
- Solid-state control.
- Reproducible cap-dependent endonuclease potency.
- Process patents covering intermediates or purification.
- Regulatory bioequivalence requirements.
Manufacturing patents may be weaker than composition claims but can increase development cost and delay launch. They are most important when the claimed process is necessary to produce the approved form at commercial scale.
Key Takeaways
- US 8,987,441 is a broad chemical patent directed to influenza cap-dependent endonuclease inhibitors.
- Claim 1 covers a formula (I) compound genus, salts, solvates, and extensive substituent classes.
- Claims 28 and 29 appear to provide narrower, commercially focused fallback positions.
- Claims 30 through 32 cover compositions with anti-influenza and cap-dependent endonuclease inhibitory activity.
- The patent is associated with the baloxavir/Xofluza patent estate and has a nominal term running to approximately March 31, 2031, subject to the official term record.
- Exact coverage of baloxavir marboxil cannot be established from the supplied text because the formula and referenced structural figures are missing.
- The principal generic risk is a Paragraph IV challenge directed to the core compound, claim construction, written description, enablement, or obviousness.
- The patent should be analyzed with later compound, formulation, method-of-use, solid-form, and manufacturing patents before estimating launch timing or revenue exposure.
FAQs
Is US 8,987,441 a compound patent or a formulation patent?
It is principally a compound patent. It also contains pharmaceutical composition claims, but the core protection is directed to defined chemical structures and their salts and solvates.
Does US 8,987,441 claim baloxavir marboxil specifically?
The supplied text does not establish that conclusion because the formula (I) drawing and several referenced structures are absent. A definitive answer requires mapping baloxavir marboxil atom by atom to the issued claims.
Can a generic avoid US 8,987,441 by using a different salt?
Not necessarily. Claim 1 expressly includes pharmaceutically acceptable salts and solvates. A different salt may still infringe if the underlying compound falls within the claimed genus.
Does claim 32 cover every influenza endonuclease inhibitor?
No. Claim 32 depends on the composition claim and therefore requires a compound covered by the incorporated chemical claims in addition to cap-dependent endonuclease inhibitory activity.
Is a Paragraph IV challenge likely to block FDA approval automatically?
No. A Paragraph IV certification initiates a patent dispute. A timely infringement action can trigger a 30-month stay of final approval, but the patent may later be found invalid, not infringed, or unenforceable. [3]
References
- United States Patent and Trademark Office. (2015). U.S. Patent No. 8,987,441, compounds and pharmaceutical compositions having anti-influenza activity.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application regulations and patent certification procedures.
- Shionogi & Co., Ltd. (n.d.). Xofluza (baloxavir marboxil) prescribing information.
